RxDoctor Payments Data

Rebecca Lockwood

Family · Asheville, NCNPI 1982940417

Payments from drug & device makers

$5,073in general payments, 2019–2025

Across 222 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Novo Nordisk$691
  • AstraZeneca$512
  • Dexcom, Inc.$435
  • Insulet Corporation$343
  • Tandem Diabetes Care, Inc.$258
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,059100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,073 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$205,687
MounjaroTirzepatide64$136,281
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/796$131,124
Humalog Kwikpen U-200Insulin Lispro30$108,444
Tresiba Flextouch U-200Insulin Degludec55$88,696
Tresiba Flextouch U-100Insulin Degludec114$80,710
JardianceEmpagliflozin53$60,044
TrulicityDulaglutide33$55,512
FiaspInsulin Aspart (Niacinamide)25$47,727
Fiasp FlextouchInsulin Aspart (Niacinamide)42$40,120
Gvoke Hypopen 2-PackGlucagon27$18,070
Lyumjev Kwikpen U-100Insulin Lispro-Aabc21$17,824
LyumjevInsulin Lispro-Aabc15$17,510
FarxigaDapagliflozin Propanediol23$13,550
NovologInsulin Aspart41$12,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$691$266,341200 claims
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro$1,145$222,687156 claims
Boehringer IngelheimJardiance$163$60,04453 claims
AstraZenecaFarxiga$512$13,55023 claims
AbbVieSynthroid$166$1,97321 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$32$98888 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →